Selected research
Industry Research
Leptospirosis Vaccine Industry Research Report 2026
Market perspective
The global Leptospirosis Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Leptospirosis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Leptospirosis Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Leptospirosis Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Leptospirosis Vaccine include Boehringer Ingelheim, Durvet, Hipra, NeoTech, Virbac, Elanco, Merck Animal Health and Zoetis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Leptospirosis Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Leptospirosis Vaccine Market by Company
Boehringer Ingelheim
Durvet
Hipra
NeoTech
Virbac
Elanco
Merck Animal Health
Zoetis
Leptospirosis Vaccine Segment by Type
Inactivated Vaccines
Live Attenuated Vaccines
Leptospirosis Vaccine Segment by Application
Puppies
Adult Dogs
Leptospirosis Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Leptospirosis Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Leptospirosis Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Leptospirosis Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Leptospirosis Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Leptospirosis Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Leptospirosis Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Inactivated Vaccines
- Live Attenuated Vaccines
Applications
- Puppies
- Adult Dogs
Companies covered
- Boehringer Ingelheim
- Durvet
- Hipra
- NeoTech
- Virbac
- Elanco
- Merck Animal Health
- Zoetis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Leptospirosis Vaccine Market Size (2021-2032)
- 2.2.2 Global Leptospirosis Vaccine Sales (2021-2032)
- 2.2.3 Global Leptospirosis Vaccine Market Average Price (2021-2032)
- 2.3 Leptospirosis Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Inactivated Vaccines
- 2.3.3 Live Attenuated Vaccines
- 2.4 Leptospirosis Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Puppies
- 2.4.3 Adult Dogs
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Leptospirosis Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Leptospirosis Vaccine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Leptospirosis Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Leptospirosis Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Leptospirosis Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Leptospirosis Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Leptospirosis Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Leptospirosis Vaccine, Established Date
- 3.9 Global Leptospirosis Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Boehringer Ingelheim
- 4.1.1 Boehringer Ingelheim Company Information
- 4.1.2 Boehringer Ingelheim Business Overview
- 4.1.3 Boehringer Ingelheim Leptospirosis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Boehringer Ingelheim Leptospirosis Vaccine Product Portfolio
- 4.1.5 Boehringer Ingelheim Recent Developments
- 4.2 Durvet
- 4.2.1 Durvet Company Information
- 4.2.2 Durvet Business Overview
- 4.2.3 Durvet Leptospirosis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Durvet Leptospirosis Vaccine Product Portfolio
- 4.2.5 Durvet Recent Developments
- 4.3 Hipra
- 4.3.1 Hipra Company Information
- 4.3.2 Hipra Business Overview
- 4.3.3 Hipra Leptospirosis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Hipra Leptospirosis Vaccine Product Portfolio
- 4.3.5 Hipra Recent Developments
- 4.4 NeoTech
- 4.4.1 NeoTech Company Information
- 4.4.2 NeoTech Business Overview
- 4.4.3 NeoTech Leptospirosis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 NeoTech Leptospirosis Vaccine Product Portfolio
- 4.4.5 NeoTech Recent Developments
- 4.5 Virbac
- 4.5.1 Virbac Company Information
- 4.5.2 Virbac Business Overview
- 4.5.3 Virbac Leptospirosis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Virbac Leptospirosis Vaccine Product Portfolio
- 4.5.5 Virbac Recent Developments
- 4.6 Elanco
- 4.6.1 Elanco Company Information
- 4.6.2 Elanco Business Overview
- 4.6.3 Elanco Leptospirosis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Elanco Leptospirosis Vaccine Product Portfolio
- 4.6.5 Elanco Recent Developments
- 4.7 Merck Animal Health
- 4.7.1 Merck Animal Health Company Information
- 4.7.2 Merck Animal Health Business Overview
- 4.7.3 Merck Animal Health Leptospirosis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Merck Animal Health Leptospirosis Vaccine Product Portfolio
- 4.7.5 Merck Animal Health Recent Developments
- 4.8 Zoetis
- 4.8.1 Zoetis Company Information
- 4.8.2 Zoetis Business Overview
- 4.8.3 Zoetis Leptospirosis Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Zoetis Leptospirosis Vaccine Product Portfolio
- 4.8.5 Zoetis Recent Developments
5 Global Leptospirosis Vaccine Market Scenario by Region
- 5.1 Global Leptospirosis Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Leptospirosis Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Leptospirosis Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Leptospirosis Vaccine Sales by Region: 2027-2032
- 5.3 Global Leptospirosis Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Leptospirosis Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Leptospirosis Vaccine Revenue by Region: 2027-2032
- 5.4 North America Leptospirosis Vaccine Market Facts & Figures by Country
- 5.4.1 North America Leptospirosis Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Leptospirosis Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Leptospirosis Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Leptospirosis Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Leptospirosis Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Leptospirosis Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Leptospirosis Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Leptospirosis Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Leptospirosis Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Leptospirosis Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Leptospirosis Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Leptospirosis Vaccine Market Facts & Figures by Country
- 5.7.1 South America Leptospirosis Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Leptospirosis Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Leptospirosis Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Leptospirosis Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Leptospirosis Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Leptospirosis Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Leptospirosis Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Leptospirosis Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Leptospirosis Vaccine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Leptospirosis Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Leptospirosis Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Leptospirosis Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Leptospirosis Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Leptospirosis Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Leptospirosis Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Leptospirosis Vaccine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Leptospirosis Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Leptospirosis Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Leptospirosis Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Leptospirosis Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Leptospirosis Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Leptospirosis Vaccine Value Chain Analysis
- 8.1.1 Leptospirosis Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Leptospirosis Vaccine Production Mode & Process
- 8.2 Leptospirosis Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Leptospirosis Vaccine Distributors
- 8.2.3 Leptospirosis Vaccine Customers
9 Global Leptospirosis Vaccine Analyzing Market Dynamics
- 9.1 Leptospirosis Vaccine Industry Trends
- 9.2 Leptospirosis Vaccine Industry Drivers
- 9.3 Leptospirosis Vaccine Industry Opportunities and Challenges
- 9.4 Leptospirosis Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst